European Journal of Cancer and Clinical Oncology
PaperLong-term survival in ovarian cancer: Mature data from The Netherlands joint study group for ovarian cancer
References (6)
- et al.
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma
Lancet
(1984) - et al.
Randomised trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma
J Clin Oncol
(1987) - et al.
Interpretation of survival data in clinical trials
Oncology
(1991)
Cited by (249)
Nanoemulsions for antitumor activity
2022, Food, Medical, and Environmental Applications of NanomaterialsA water-soluble polysaccharide from the roots of Polygala tenuifolia suppresses ovarian tumor growth and angiogenesis in vivo
2018, International Journal of Biological MacromoleculesThe impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period
2016, Surgical OncologyCitation Excerpt :Once a diagnosis has been made, it is important to determine potential outcomes based on prognostic factors that will enable us to estimate the probability of recovery. In EOC, favorable independent predictors for 5-year overall survival (OS) include younger age, good performance status, histological type other than mucinous or clear cell, well-differentiated tumor grade, early stage, smaller tumor volume before surgical debulking, no residual tumor after debulking, and absence of ascites [11–16]. Close monitoring ensures that recurrence is readily identified and chemotherapy can be restarted in an attempt to turn the disease into a chronic process.
Why have ovarian cancer mortality rates declined? Part II. Case-fatality
2015, Gynecologic OncologyCitation Excerpt :Across studies, median progression-free survival was about six months and median overall survival was about 12 months. After 10 years of follow-up, 95% of patients had progressed and 90% of patients had died [8,9]. Cisplatin was approved for the treatment of ovarian cancer in the United States in 1978.
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study
2009, Gynecologic OncologyCitation Excerpt :Epithelial ovarian cancer remains a leading cause of mortality from gynaecologic malignancies in Western countries, which mainly results from a late diagnosis [1-9].